Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 Piotroski F-Score is 4 as of Aug. 01, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 980 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 61.53% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Accretion Nutraveda has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Accretion Nutraveda's Piotroski F-Score or its related term are showing as below:
BOM:544694'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 5
Current: 4
During the past 4 years, the highest Piotroski F-Score of Accretion Nutraveda was 5. The lowest was 4. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Accretion Nutraveda Piotroski F-Score Related Terms
Accretion Nutraveda Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda Piotroski F-Score Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Piotroski F-Score
N/A
N/A
5.00
4.00
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Piotroski F-Score
N/A
N/A
5.00
0.00
4.00
BOM:544694 vs ZTS: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Accretion Nutraveda's current Net Income (TTM) was 50.7.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Accretion Nutraveda's return on assets of this year was 0.46659977. Accretion Nutraveda's return on assets of last year was 0.5391265.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Accretion Nutraveda's gearing of this year was 0.14363036. Accretion Nutraveda's gearing of last year was 0.19818076.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Accretion Nutraveda's current ratio of this year was 14.26833399. Accretion Nutraveda's current ratio of last year was 2.23873156.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Accretion Nutraveda's number of shares in issue this year was 5.421. Accretion Nutraveda's number of shares in issue last year was 7.24.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Accretion Nutraveda's gross margin of this year was 0.28267928. Accretion Nutraveda's gross margin of last year was 0.33959305.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Accretion Nutraveda's asset turnover of this year was 3.09358141. Accretion Nutraveda's asset turnover of last year was 3.44955592.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
0
+
0
+
0
+
1
+
1
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Accretion Nutraveda has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Accretion Nutraveda (BOM:544694) has a Piotroski F-Score of 4 as of Aug. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Accretion Nutraveda and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Accretion Nutraveda's Piotroski F-Score has ranged from 4.00 to 5.00. According to the industry distribution chart, Accretion Nutraveda ranks #603 out of 980 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is Accretion Nutraveda's Piotroski F-Score too high?
Accretion Nutraveda's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Accretion Nutraveda's value of 4 is 20% below this industry median. Based on the distribution chart, Accretion Nutraveda ranks #603 out of 980 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #603 out of 980 companies for Piotroski F-Score. This places Accretion Nutraveda in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Accretion Nutraveda's value of 4 is 20% below this benchmark. Historically, Accretion Nutraveda's own Piotroski F-Score has ranged from 4.00 to 5.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Accretion Nutraveda has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Drug Manufacturers industry median of 5.00. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Piotroski F-Score is 4 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
